EANS-Adhoc: AGENNIX AG / Agennix AG Raises Approximately EUR 76 Million in Net Proceeds in Capital Increase

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

01.10.2010

Planegg/Munich (Germany), October 1, 2010 - Agennix AG (Frankfurt Stock Exchange
(Prime Standard): AGX/ISIN DE000A1A6XX4) today announced that the Company has
raised approximately EUR 76 million in net proceeds in its capital increase
via participation from both new and existing shareholders. The execution of the
capital increase is based on the resolution passed at the Company´s annual
general meeting on May 25, 2010 to issue 20,588,705 new shares, which will
result in a total of 41,413,846 shares issued and outstanding. Subscription
rights have been granted to the shareholders. The subscription price was EUR
3.81 per share.

In the capital increase, approximately 29% of the 20,588,705 new shares were
subscribed in the rights offering and approximately 71% of the shares were
purchased by new institutional investors in a private placement or by dievini
Hopp BioTech holding GmbH & Co. KG under a firm commitment agreement.

Following the completion of this offering, dievini will hold approximately 59%
of shares outstanding in Agennix. Dievini has informed the Company that it has
not yet received a decision from the German Federal Financial Supervisory
Authority (Bundesanstalt fuer Finanzdienstleistungsaufsicht) (BaFin) regarding
dievini´s application for an exemption from the obligation to make a mandatory
tender offer. Dievini applied for this exemption in case it acquired control of
the Company in the meaning of Section 29 (2) of the German Takeover Act through
participation in the capital increase.

The entry of the capital increase in the commercial register of the local court
in Mannheim is expected to occur on or around October 4, 2010. The new shares
will be listed on the Frankfurt Stock Exchange and are expected to begin trading
on or around October 5, 2010. The Joint Global Coordinators for the transaction
were Piper Jaffray Ltd. and WestLB AG.
END OF AD HOC ANNOUNCEMENT
About Agennix

Agennix AG is a publicly listed biopharmaceutical company that is focused on the
development of novel therapies that have the potential to substantially improve
the length and quality of life of critically ill patients in areas of major
unmet medical need. The Company´s most advanced program is talactoferrin, an
oral therapy that has demonstrated activity in randomized, double-blind,
placebo-controlled Phase II studies in non-small cell lung cancer, as well as in
severe sepsis. Talactoferrin is currently in Phase III clinical trials in
non-small cell lung cancer, and Agennix plans to develop this program further
for the treatment of severe sepsis. Other clinical development programs include
RGB-286638, a multi-targeted kinase inhibitor in Phase I testing; the oral
platinum-based compound satraplatin; and a topical gel form of talactoferrin for
diabetic foot ulcers. Agennix´s registered seat is in Heidelberg, Germany. The
Company has three sites of operation: Planegg/Munich, Germany; Princeton, New
Jersey and Houston, Texas. For additional information, please visit the Agennix
Web site at www.agennix.com.

This ad hoc announcement contains forward-looking statements, which express the
current beliefs and expectations of the management of Agennix AG. Such
statements are based on current expectations and are subject to risks and
uncertainties, many of which are beyond our control, that could cause future
results, performance or achievements to differ significantly from the results,
performance or achievements expressed or implied by such forward-looking
statements. Actual results could differ materially depending on a number of
factors, and we caution investors not to place undue reliance on the
forward-looking statements contained in this ad hoc announcement.
Forward-looking statements speak only as of the date on which they are made and
Agennix undertakes no obligation to update these forward-looking statements,
even if new information becomes available in the future.

This ad hoc announcement is not for distribution, directly or indirectly, in or
into the United States (including its territories and possessions, any State of
the United States and the District of Columbia). These materials do not
constitute or form a part of any offer or solicitation to purchase or subscribe
for securities in the United States of America. The shares in Agennix AG (the
"Shares") mentioned herein may not be offered or sold in the United States
absent registration or an exemption from registration under the U.S. Securities
Act of 1933, as amended (the "Securities Act").

The Shares have not been, and will not be, registered under the Securities Act
and will not be offered or sold in the United States, except on the basis of
applicable exemptions from registration. There will be no public offering of
securities in the United States.

Further inquiry note:
For further information, please contact:

Agennix AG
Investor Relations & Corporate Communications

Phone: +49 (0)89 8565 2693      
[email protected]  
        
In the U.S.: Laurie Doyle

Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884
[email protected]

Additional media contact for Europe:
MC Services AG
Raimund Gabriel
Phone: +49 (0) 89 210 228 0
[email protected]

Additional investor contact for Europe:
Trout International LLC
Lauren Williams, Vice President
Phone: +44 207 936 9325
[email protected]
end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer:      AGENNIX AG
             Im Neuenheimer Feld 515
             D-69120 Heidelberg
phone:       +49 89 8565 2693
FAX:         +49 89 8565 2610
mail:        [email protected]
WWW:         http://www.agennix.com
sector:      Pharmaceuticals
ISIN:        DE000A1A6XX4
indexes:     CDAX, Prime All Share, Technology All Share

stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
Hamburg, Düsseldorf, Hannover, München
language: English

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | OTB

print